Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02461745 · ClinicalTrials.gov registry record · Phase 4
Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO
A Phase 4 study, sponsored by Kaiser Permanente.
- Completed
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT02461745: Completed Phase 4 study, sponsored by Kaiser Permanente.
NCT02461745 is a Phase 4 study that has completed, run by Kaiser Permanente. The registered enrollment target is 200 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02461745, a Phase 4 study, has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
This is a Phase IV, open-label, multi-center study to evaluate the real world sustained virological response rate, subject adherence, and subject reported outcomes during and after treatment of non-cirrhotic genotype 1 chronic hepatitis C subjects aged 18 years and older, with VIEKIRA PAK (ombitasvir, paritaprevir/r, dasabuvir), with or without RBV (ribavirin).
Primary Outcome
Percentage of study participants achieving sustained virological response (SVR) at Week 12 per protocol among study participants who completed 12-week course of treatment.
Interventions
- DRUG ombitasvir, paritaprevir/r, dasabuvir + ribavirin
- DRUG ombitasvir, paritaprevir/r, dasabuvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-05 |
| Phase | Phase 4 |
What the finished NCT02461745 record still lists
NCT02461745 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 2 interventions - of which ombitasvir, paritaprevir/r, dasabuvir + ribavirin is the first listed.
NCT02461745 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02461745 about?
NCT02461745 is a clinical study titled "Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO". This is a Phase IV, open-label, multi-center study to evaluate the real world sustained virological response rate, subject adherence, and subject reported outcomes during and after treatment of non-cirrhotic genotype 1 chronic hepatitis C subjects aged 18 years and older, with VIEKIRA PAK (ombitasvi...
What is the current status of trial NCT02461745?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2015-06. Estimated completion is 2017-05.
What interventions are being tested in trial NCT02461745?
The interventions under investigation include: ombitasvir, paritaprevir/r, dasabuvir + ribavirin (DRUG), ombitasvir, paritaprevir/r, dasabuvir (DRUG).
Who is sponsoring clinical trial NCT02461745?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02461745's enrollment target sits among peer trials
200 407th of 2000 higher than 1,556 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia